VRX Related Mergers and Acquisitions
-
Valeant (VRX) Continues Deal Hunt; Close to Buying Bausch & Lomb for $9B
-
UPDATE: Bausch & Lomb near deal to sell to Valeant Pharmaceuticals (VRX) - WSJ
-
UPDATE: Lazard Capital Downgrades Warner Chilcott (WCRX), Says Deal Could Fall Through
-
UPDATE: Correct: Buying Warner Chilcott plc (WCRX) Seen as Takeover Defense by Actavis (ACT)
-
Actavis (ACT) Acquires Metronidazole 1.3% Gel from Valeant (VRX) in $55M + Milestones Deal
-
Actavis (ACT) / Valeant (VRX) Deal Rumored Down But Not Out
-
Valeant Pharmaceuticals (VRX) Near Deal to Acquire Actavis (ACT) for Over $13B
-
Merz Pharma Withdraws $22/Share Bid for Obagi Medical (OMPI)
-
Valeant (VRX) May Tuck Tail if Obagi (OMPI) Bidding War Heats Up - Analyst
-
Valeant Pharmaceuticals (VRX) Raises Offer for Obagi Medical (OMPI) to $24/Sh
-
Obagi Medical (OMPI) Bidding War Could Take Stock as High as $27/Share
-
Merz Pharma Tops Valeant (VRX) Offer for Obagi Medical Products (OMPI), Offers $22/Share
-
Valeant Pharma (VRX) to Acquire Obagi Medical (OMPI) for $19.75/Share
-
Valeant Pharma (VRX) Reaches Agreement with Galderma; Will Make Upfront Payment (MRX)
-
Valeant (VRX) Receives FTC Clearance to Acquire Medicis Pharma (MRX)
-
QLT (QLTI) Completes $112.5M Sale of Visudyne to Valeant (VRX)
-
Jefferies Maintains a 'Buy/Top Pick' on Valeant Pharmaceuticals (VRX); Taking the Right Medic(is)ine
-
Barclays Maintains an 'Equalweight' on Medicis (MRX); Is Another Bidder Out There?
-
UBS Maintains a 'Buy' on Valeant Pharmaceuticals (VRX); Deal Supports Thesis; Stock Move Justified
-
Goldman Sachs Downgrades Medicis (MRX) to Neutral; Limited Upside From Deal Now
-
Barclays on Medicis (MRX)/Valeant (VRX) Deal: Surprise...or Not Really?
-
Canaccord Genuity Maintains a 'Hold' on Medicis (MRX); Key Question Around Acquisition Is...
-
Cantor Fitzgerald Maintains a 'Hold' on Medicis (MRX); Acquisition Rewarding Patient Investors
-
Valeant (VRX) to Acquire Medicis (MRX) to $44/Share; Deal Valued at $2.6B
-
Valeant Pharma (VRX) to Acquire OraPharma in $312M Deal; Could Add $114M in Contingent Payments
-
Valeant Pharma (VRX) Will Buy Swiss Herbal Remedies
-
Valeant Pharma (VRX) to Buy Assets from Atlantis Pharma for $71M
-
Valeant (VRX) Acquires Podiatry-Focused Co. Pedinol Pharmacal
-
Valeant Pharma (VRX) to Buy Naktur Produkt for $180M
-
Valeant (VRX) to Buy 19.9% Stake in Pele Nova Biotecnologia
-
Valeant Pharma (VRX) Buys Eyetech
-
Valeant Pharma (VRX) Acquires Probiotica Laboratorios in R$150M Deal
-
ISTA (ISTA) to Continue Review of Strategic Options
-
ISTA Pharma (ISTA) About 6% Lowe; Valeant (VRX) Withdraws Offer
-
Valeant Pharma (VRX) Withdraws $7.50/Share Bid for ISTA Pharma (ISTA)
-
Valeant Pharma (VRX) Boosts Bid for ISTA Pharma (ISTA) to $7.50/Share
-
ISTA Pharma (ISTA) Gets $7.50/Share Bid from Valeant Pharma (VRX) w/ Target of $8.50/Share
-
ISTA Pharma (ISTA) Rejects Unsolicited $6.50/Share Valeant (VRX) Offer
-
ISTA Pharma (ISTA) Pops 66%+ Following Valeant (VRX) Proposal
-
Valeant Pharmaceuticals (VRX) Offers to Acquire ISTA Pharmaceuticals Inc. (ISTA) for $6.50/Share
-
Valeant (VRX) Gets FTC Approval for Consent Orders in Dermik, Ortho Dermatologics Acquisitions
-
Valeant (VRX) to Acquire iNova in A$700M Deal
-
Valeant (VRX) Updates on Afexa Tender; Holds 81.6% of All Outstanding Common
-
Valeant (VRX) Updates on Afexa Tender Offer
-
Afexa Board Recommends Tender for Increased Valeant (VRX) Offer
-
Valeant (VRX) to Raise Bid for Afexa by 20% to 85c/Share
-
Valeant Pharma (VRX) Receives Two Additional FTC Requests for Info in Dermatology Acquisitions
-
Valeant Pharmaceuticals (VRX) Announces Acquisition of Afexa Life Sciences for C$76 Million
-
Valeant (VRX) Approached Medicis Pharma (MRX) About Potential Sale -WSJ
-
Valeant Pharmaceuticals (VRX) Makes $4B+ Bid for Meda - WSJ
Back to VRX Stock Lookup
